Further evidence for the adverse impact of CD164 expression on GBM progression was found upon analysis of astrocytoma/glioma PRECOG datasets, which showed a significant, inverse correlation between CD164 levels and survival rates. The gene discussed is CD164; the disease is astrocytoma (excluding glioblastoma).